
Eroboghene E Ubogu

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6371153/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	The expression and function of chemokines involved in CNS inflammation. Trends in Pharmacological Sciences, 2006, 27, 48-55.	8.7	260
2	Inflammatory Cell Migration into the Central Nervous System: A Few New Twists on an Old Tale. Brain Pathology, 2007, 17, 243-250.	4.1	214
3	Modulating CCR2 and CCL2 at the blood–brain barrier: relevance for multiple sclerosis pathogenesis. Brain, 2006, 129, 212-223.	7.6	188
4	Ketamine for refractory status epilepticus: a case of possible ketamine-induced neurotoxicity. Epilepsy and Behavior, 2003, 4, 70-75.	1.7	103
5	Human Brain Microvascular Endothelial Cells and Umbilical Vein Endothelial Cells Differentially Facilitate Leukocyte Recruitment and Utilize Chemokines for T Cell Migration. Clinical and Developmental Immunology, 2008, 2008, 1-8.	3.3	85
6	Determinants of CCL5-driven mononuclear cell migration across the blood–brain barrier. Implications for therapeutically modulating neuroinflammation. Journal of Neuroimmunology, 2006, 179, 132-144.	2.3	70
7	"Small Blood Vessels: Big Health Problems?â€: Scientific Recommendations of the National Institutes of Health Workshop. Journal of the American Heart Association, 2016, 5, .	3.7	67
8	Inflammatory neuropathies: pathology, molecular markers and targets for specific therapeutic intervention. Acta Neuropathologica, 2015, 130, 445-468.	7.7	60
9	The Molecular and Biophysical Characterization of the Human Blood-Nerve Barrier: Current Concepts. Journal of Vascular Research, 2013, 50, 289-303.	1.4	56
10	CCR5 expression on monocytes and T cells: Modulation by transmigration across the blood–brain barrier in vitro. Cellular Immunology, 2006, 243, 19-29.	3.0	47
11	Development and Characterization of a Novel Human In Vitro Blood-Nerve Barrier Model Using Primary Endoneurial Endothelial Cells. Journal of Neuropathology and Experimental Neurology, 2010, 69, 82-97.	1.7	46
12	Clinical features of <scp>LRP4</scp> /agrinâ€antibody–positive myasthenia gravis: A multicenter study. Muscle and Nerve, 2020, 62, 333-343.	2.2	46
13	Cervicomedullary junction compression caused by vertebral artery dolichoectasia and requiring surgical treatment. Journal of Neurosurgery, 2002, 96, 140-143.	1.6	42
14	Dorsal caudal tail and sciatic motor nerve conduction studies in adult mice: Technical aspects and normative data. Muscle and Nerve, 2010, 41, 850-856.	2.2	40
15	Biology of the human blood-nerve barrier in health and disease. Experimental Neurology, 2020, 328, 113272.	4.1	40
16	Osteoblasts Have a Neural Origin in Heterotopic Ossification. Clinical Orthopaedics and Related Research, 2015, 473, 2790-2806.	1.5	38
17	Mirtazapine-Induced Serotonin Syndrome. Clinical Neuropharmacology, 2003, 26, 54-57.	0.7	36
18	Adult polyglucosan body disease: A case report of a manifesting heterozygote. Muscle and Nerve, 2005, 32, 675-681.	2.2	36

#	Article	IF	CITATIONS
19	Predictors of Clinical Outcome and Mortality in Vertebrobasilar Dolichoectasia Diagnosed by Magnetic Resonance Angiography. Journal of Stroke and Cerebrovascular Diseases, 2008, 17, 388-393.	1.6	35
20	Transient Brown Adipocyte-Like Cells Derive from Peripheral Nerve Progenitors in Response to Bone Morphogenetic Protein 2. Stem Cells Translational Medicine, 2012, 1, 874-885.	3.3	35
21	The Human Blood-Nerve Barrier Transcriptome. Scientific Reports, 2017, 7, 17477.	3.3	33
22	An Immortalized Human Blood-Nerve Barrier Endothelial Cell Line for In Vitro Permeability Studies. Cellular and Molecular Neurobiology, 2013, 33, 175-186.	3.3	32
23	Immunotherapy of Guillain-Barré syndrome. Human Vaccines and Immunotherapeutics, 2018, 14, 1-12.	3.3	32
24	Clinical, electrophysiological and pathologic correlations in a severe murine experimental autoimmune neuritis model of Guillain–Barré syndromeâ~†. Journal of Neuroimmunology, 2010, 219, 54-63.	2.3	31
25	The role of chemokines in guillain–barré syndrome. Muscle and Nerve, 2013, 48, 320-330.	2.2	31
26	α _M β ₂ â€integrinâ€intercellular adhesion moleculeâ€1 interactions drive the flowâ€dependent trafficking of Guillain–Barré syndrome patient derived mononuclear leukocytes at the blood–nerve barrier in vitro. Journal of Cellular Physiology, 2012, 227, 3857-3875.	4.1	28
27	Behavioral, electrophysiological, and histopathological characterization of a severe murine chronic demyelinating polyneuritis model. Journal of the Peripheral Nervous System, 2012, 17, 53-61.	3.1	28
28	CCR2 Gene Deletion and Pharmacologic Blockade Ameliorate a Severe Murine Experimental Autoimmune Neuritis Model of Guillain-Barré Syndrome. PLoS ONE, 2014, 9, e90463.	2.5	27
29	GDNF restores human blood–nerve barrier function via RET tyrosine kinase-mediated cytoskeletal reorganization. Microvascular Research, 2012, 83, 298-310.	2.5	23
30	Rectus Sheath Hematoma Complicating Percutaneous Endoscopic Gastrostomy. Surgical Laparoscopy, Endoscopy and Percutaneous Techniques, 2002, 12, 430-432.	0.8	21
31	VEGF-A165 Potently Induces Human Blood–Nerve Barrier Endothelial Cell Proliferation, Angiogenesis, and Wound Healing In Vitro. Cellular and Molecular Neurobiology, 2013, 33, 789-801.	3.3	20
32	The pathogenic relevance of αM-integrin in Guillain–Barré syndrome. Acta Neuropathologica, 2016, 132, 739-752.	7.7	20
33	Transverse myelitis associated with Acinetobacter baumanii intrathecal pump catheter-related infection. Regional Anesthesia and Pain Medicine, 2003, 28, 470-474.	2.3	19
34	Acute Motor-Sensory Axonal Neuropathy Associated with Active Systemic Lupus Erythematosus and Anticardiolipin Antibodies. Journal of Clinical Rheumatology, 2001, 7, 326-331.	0.9	18
35	Modeling leukocyte trafficking at the human blood-nerve barrier in vitro and in vivo geared towards targeted molecular therapies for peripheral neuroinflammation. Journal of Neuroinflammation, 2016, 13, 3.	7.2	15
36	Interferon-α-2b/ribavirin-induced vestibulocochlear toxicity with dysautonomia in a chronic hepatitis C patient. European Journal of Gastroenterology and Hepatology, 2008, 20, 1110-1114.	1.6	14

EROBOGHENE E UBOGU

#	Article	IF	CITATIONS
37	Chemokine Receptors as Specific Anti-Inflammatory Targets in Peripheral Nerves. Endocrine, Metabolic and Immune Disorders - Drug Targets, 2011, 11, 141-153.	1.2	14
38	Fibronectin connecting segment-1 peptide inhibits pathogenic leukocyte trafficking and inflammatory demyelination in experimental models of chronic inflammatory demyelinating polyradiculoneuropathy. Experimental Neurology, 2017, 292, 35-45.	4.1	14
39	VIP-expressing Dendritic Cells Protect Against Spontaneous Autoimmune Peripheral Polyneuropathy. Molecular Therapy, 2014, 22, 1353-1363.	8.2	13
40	A novel method for measuring hydraulic conductivity at the human blood-nerve barrier in vitro. Microvascular Research, 2017, 109, 1-6.	2.5	13
41	Amaurosis fugax Associated with Phencyclidine Inhalation. European Neurology, 2001, 46, 98-99.	1.4	12
42	Electrodiagnostic criteria for carpal tunnel syndrome in axonal polyneuropathy. Muscle and Nerve, 2006, 33, 747-752.	2.2	12
43	Complete innervation of extensor digitorum brevis by accessory peroneal nerve. Neuromuscular Disorders, 2005, 15, 562-564.	0.6	11
44	GDNF enhances human blood-nerve barrier function <i>in vitro</i> via MAPK signaling pathways. Tissue Barriers, 2018, 6, 1-22.	3.2	10
45	In situ molecular characterization of endoneurial microvessels that form the bloodâ€nerve barrier in normal human adult peripheral nerves. Journal of the Peripheral Nervous System, 2019, 24, 195-206.	3.1	9
46	Recurrent Transient Ischemic Attacks as the Initial Presenting Manifestation of Type A Aortic Dissection. Annals of Vascular Surgery, 2002, 16, 676-678.	0.9	8
47	Chemokine-Dependent Signaling Pathways in the Peripheral Nervous System. Methods in Molecular Biology, 2013, 1013, 17-30.	0.9	8
48	The preferential involvement of extraocular muscles by myasthenia gravis. Neuro-Ophthalmology, 2001, 25, 219-228.	1.0	7
49	Translational strategies in peripheral neuroinflammation and neurovascular repair. Translational Neuroscience, 2012, 3, 373-383.	1.4	7
50	Glial-derived neurotrophic factor is essential for blood-nerve barrier functional recovery in an experimental murine model of traumatic peripheral neuropathy. Tissue Barriers, 2018, 6, 1-22.	3.2	7
51	Chronic inflammatory demyelinating polyradiculoneuropathy presenting as cauda equina syndrome in a diabetic. Journal of the Neurological Sciences, 2007, 260, 267-270.	0.6	6
52	Intracranial arterial dolichoectasia is associated with enlarged descending thoracic aorta. Neurology, 2005, 65, 1681-1682.	1.1	4
53	"Doing the locomotion―with the multistep paradigm. Blood, 2007, 109, 1342-1343.	1.4	4
54	Subacute brachial diplegia associated with west nile virus myelitis. Muscle and Nerve, 2012, 45, 900-904.	2.2	4

EROBOGHENE E UBOGU

#	Article	IF	CITATIONS
55	Acute myofascitis as a manifestation of chronic graft-versus-host disease. Muscle and Nerve, 2016, 53, 327-329.	2.2	4
56	Otalgia as the sole presenting manifestation of subdural hematoma. American Journal of Otolaryngology - Head and Neck Medicine and Surgery, 2002, 23, 177-180.	1.3	3
57	Adverse Reactions to Mirtazapine are Unlikely to be Serotonin Toxicity and Mirtazapine: Unable to Induce Serotonin Toxicity?–Response. Clinical Neuropharmacology, 2003, 26, 289-290.	0.7	3
58	Clinical and radiological features of symptomatic cerebral perfusion failure due to carotid artery occlusion surgically corrected by extracranialintracranial bypass surgery. Journal of Neurology, 2004, 251, 613-616.	3.6	1
59	Glial derived neurotrophic factor: a sufficient essential molecular regulator of mammalian blood-nerve barrier tight junction formation. Neural Regeneration Research, 2021, 16, 1417.	3.0	1
60	Atypical Motor Neuron Disorders. , 2014, , 441-466.		0
61	Structural and Functional Characteristics of the Human Blood-Nerve Barrier with Translational Implications to Peripheral Nerve Autoimmune Disorders. , 2019, , 235-302.		0
62	Fibulin-5 mutation featuring Charcot-Marie-Tooth disease, joint hyperlaxity, and scoliosis. Neurology: Genetics, 2020, 6, e476.	1.9	0